---
title: "TD Cowen Reaffirms Their Buy Rating on Charles River Labs (CRL)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295351253.md"
description: "TD Cowen analyst Charles Rhyee reaffirmed a Buy rating on Charles River Labs (CRL) with a $300 price target. Rhyee, a 4-star analyst in the Healthcare sector, maintains this stance alongside a broader market consensus of Strong Buy for CRL, which carries an average price target of $281.55."
datetime: "2026-08-10T02:55:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295351253.md)
  - [en](https://longbridge.com/en/news/295351253.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295351253.md)
generator: "portal-rs"
---

# TD Cowen Reaffirms Their Buy Rating on Charles River Labs (CRL)

TD Cowen analyst Charles Rhyee maintained a Buy rating on Charles River Labs yesterday and set a price target of $300.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Rhyee is a 4-star analyst with an average return of 5.5% and a 53.25% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as Charles River Labs, Icon, and McKesson.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Charles River Labs with a $281.55 average price target.

### Related Stocks

- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)
- [ICLR.US](https://longbridge.com/en/quote/ICLR.US.md)
- [MCK.US](https://longbridge.com/en/quote/MCK.US.md)

## Related News & Research

- [Insider Move at Charles River Labs: Director Cashes In on Company Stock](https://longbridge.com/en/news/296571643.md)
- [Charles River Labs director Nancy C. Andrews disposes of 573 common shares worth $163,442.52](https://longbridge.com/en/news/296533503.md)
- [Charles River and MVC to develop enterovirus vaccine](https://longbridge.com/en/news/296594849.md)
- [Charles River partners with Medigen Vaccine Biologics on NGS-backed multivalent enterovirus vaccine development](https://longbridge.com/en/news/296486690.md)
- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**